Abeona Therapeutics (NASDAQ:ABEO) was downgraded by equities researchers at BidaskClub from a “sell” rating to a “strong sell” rating in a research note issued on Thursday.
ABEO has been the subject of a number of other research reports. Cantor Fitzgerald set a $36.00 price objective on Abeona Therapeutics and gave the company a “buy” rating in a research note on Friday, August 17th. Zacks Investment Research raised Abeona Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, July 24th. Maxim Group reissued a “buy” rating and set a $26.00 price objective on shares of Abeona Therapeutics in a research note on Monday, November 5th. ValuEngine lowered Abeona Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, August 30th. Finally, TheStreet lowered Abeona Therapeutics from a “c-” rating to a “d+” rating in a research note on Wednesday, August 29th. One analyst has rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $25.90.
NASDAQ:ABEO opened at $9.36 on Thursday. The company has a market cap of $419.98 million, a PE ratio of -14.18 and a beta of 1.77. Abeona Therapeutics has a fifty-two week low of $8.52 and a fifty-two week high of $22.00.
Abeona Therapeutics (NASDAQ:ABEO) last released its quarterly earnings data on Friday, August 10th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.06). The company had revenue of $0.82 million for the quarter, compared to analysts’ expectations of $1.81 million. Abeona Therapeutics had a negative net margin of 881.74% and a negative return on equity of 23.02%. As a group, sell-side analysts forecast that Abeona Therapeutics will post -0.88 EPS for the current year.
A number of hedge funds have recently made changes to their positions in the stock. Trexquant Investment LP purchased a new stake in Abeona Therapeutics in the third quarter worth $163,000. FMR LLC lifted its stake in Abeona Therapeutics by 1.4% in the third quarter. FMR LLC now owns 7,191,492 shares of the biopharmaceutical company’s stock worth $92,051,000 after acquiring an additional 97,185 shares during the period. BlackRock Inc. lifted its stake in Abeona Therapeutics by 1.6% in the third quarter. BlackRock Inc. now owns 2,220,116 shares of the biopharmaceutical company’s stock worth $28,418,000 after acquiring an additional 35,610 shares during the period. SG Americas Securities LLC purchased a new stake in Abeona Therapeutics in the third quarter worth $235,000. Finally, Creative Planning purchased a new stake in Abeona Therapeutics in the third quarter worth $875,000. 76.38% of the stock is owned by institutional investors.
Abeona Therapeutics Company Profile
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
See Also: Technical Analysis of Stocks, How Can It Help
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.